US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Militia Long/Short Equity ETF

38.54

+0.07000.18%

Post-market: 38.540.00000.00%18:21 EST

Volume:364.69K

Turnover:13.98M

Market Cap:391.95M

PE:- -

High:38.60

Open:38.32

Low:38.10

Close:38.47

52wk High:38.78

52wk Low:25.85

Shares:10.17M

Float Shares:10.17M

Volume Ratio:0.78

T/O Rate:3.59%

Dividend:- -

Dividend Rate:- -

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Press Release: ORYZON Announces Appointment of Rolando Gutierrez-Esteinou, M.D., as Chief Medical Officer for CNS

Replimune Reports Fiscal Third Quarter 2026 Financial Results and Provides Corporate Update

Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Provides a Corporate Update

Cardiff Oncology Announces Positive Update from its Randomized Phase 2 Trial of Onvansertib in First-line RAS-mutated mCRC

Cogent Biosciences to Initiate New Drug Application (NDA) Submission for Bezuclastinib Under Real-Time Oncology Review (RTOR)

Antengene Presents at JPM: Strong Clinical Data Update and Strategic Focus on Next-Generation ADCs and TCEs

C4 Therapeutics Outlines Strategic Milestones to Advance Cemsidomide as a Potential Best-in-Class IKZF1/3 Degrader and Discovery Strategy Focused on Novel Targets in Clinically Validated Pathways

ACCENT DATA PRESENTED AT 2026 ASCO GASTROINTESTINAL CANCER SYMPOSIUM

Press Release: Rigel Provides Business Update and 2026 Outlook

Press Release: Exelixis Announces Preliminary Fiscal Year 2025 Financial Results, Provides 2026 Financial Guidance and Outlines Key Priorities and Milestones for 2026

Cellectis Announces 2026 Strategy and Catalysts

ALX Oncology Advances Separate Clinical Trials Evaluating Investigational CD47-Inhibitor Evorpacept and Novel EGFR-Targeted Antibody-Drug Conjugate ALX2004

Acrivon Therapeutics Announces Positive ACR-368 Phase 2b Endometrial Cancer Clinical Data with EU Expansion to Accelerate Enrollment, Initial ACR-2316 Clinical Data, and ACR-6840, its Next AP3-Enabled Development Candidate, Targeting CDK11

ORR Reaches 89.5%! Zhixiang Jintai's BCMA/CD3 Bispecific Antibody Submits for Market Approval

BBOT Announces New Clinical Data Advancing Its Portfolio of Three Innovative and Differentiated RAS and PI3Kα Pipeline Programs

Ziihera® (zanidatamab-hrii) Combinations Achieve Unprecedented Results in First-Line HER2+ Locally Advanced or Metastatic GEA including more than Two Years Median Overall Survival Benefit

Alpha Tau Reports New Positive Results in Two Upcoming Presentations at ASCO GI 2026 Symposium Showcasing Immune-Preservation and High Disease Control in Montreal Pancreatic Cancer Alpha DaRT® Study

Junce Bio Focuses on "Lymphodepletion-Free" Breakthrough in Solid Tumors, GC101 Expected to Submit Marketing Application in 2026

HUTCHMED Announces NDA Acceptance in China with Priority Review Status for Fanregratinib in Second-Line Intrahepatic Cholangiocarcinoma

Lung Cancer Frontline! "Furmonertinib" New Indication Proposed for Breakthrough Therapy Designation

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/ORR/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ORR","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ORR\",,,,,undefined,":{"symbol":"ORR","market":"US","secType":"STK","nameCN":"Militia Long/Short Equity ETF","latestPrice":38.54,"timestamp":1771016400000,"preClose":38.47,"halted":0,"volume":364691,"hourTrading":{"tag":"盘后","latestPrice":38.54,"preClose":38.54,"latestTime":"18:21 EST","volume":14,"amount":541.34,"timestamp":1771024878714,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.0018195996880686323,"floatShares":10170000,"shares":10170000,"eps":0,"marketStatus":"Market Closed","change":0.07,"latestTime":"02-13 16:00:00 EST","open":38.32,"high":38.596,"low":38.1,"amount":13984167.56775,"amplitude":0.012893,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1771318800000},"marketStatusCode":7,"adr":0,"exchange":"NASDAQ","adjPreClose":38.47,"sharesOutstanding":10170000,"nav":38.43,"aum":390833100,"bidAskSpread":0,"preHourTrading":{"tag":"盘前","latestPrice":38.94,"preClose":38.47,"latestTime":"09:14 EST","volume":8,"amount":311.52,"timestamp":1770992045885,"change":0.47,"changeRate":0.012217,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":38.54,"preClose":38.54,"latestTime":"18:21 EST","volume":14,"amount":541.34,"timestamp":1771024878714,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.7803754799259959,"impliedVol":0.1551,"impliedVolPercentile":0.8889},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ORR\",,,,,undefined,":{"symbol":"ORR","floatShares":10170000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.7803754799259959,"shares":10170000,"dividePrice":0,"high":38.596,"amplitude":0.012893,"preClose":38.47,"low":38.1,"week52Low":25.85,"pbRate":"--","week52High":38.78,"institutionHeld":0,"latestPrice":38.54,"eps":0,"divideRate":0,"volume":364691,"delay":0,"ttmEps":0,"open":38.32,"prevYearClose":34.16,"prevWeekClose":37.53,"prevMonthClose":36.48,"prevQuarterClose":34.16,"fiveDayClose":37.53,"twentyDayClose":35.44,"sixtyDayClose":32.92},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ORR\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ORR\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ORR\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ORR\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2610929187","title":"Press Release: ORYZON Announces Appointment of Rolando Gutierrez-Esteinou, M.D., as Chief Medical Officer for CNS","url":"https://stock-news.laohu8.com/highlight/detail?id=2610929187","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610929187?lang=en_us&edition=fundamental","pubTime":"2026-02-12 21:00","pubTimestamp":1770901200,"startTime":"0","endTime":"0","summary":"-- Based in New Jersey , to lead ORYZON's CNS clinical development. MADRID and CAMBRIDGE, Mass., Feb. 12, 2026  -- Oryzon Genomics, S.A. , a clinical-stage biopharmaceutical company and global leader in epigenetics, today announced the appointment of Rolando Gutierrez-Esteinou, M.D., as Chief Medical Officer, CNS Programs. Dr. Gutierrez-Esteinou is a Harvard-trained psychiatrist and an accomplished global clinical development executive with more than 20 years of leadership experience advancing neuroscience and psychiatry-focused drug development programs. He brings deep expertise in late-stage clinical execution, regulatory strategy, and pathways to market approval.\"It is a privilege to join Oryzon as Chief Medical Officer and help advance vafidemstat, the onl","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4232","ORR","BK4081","CMT","USA","CNS","BK4090","EMA","BK4022","R","BK4156","BK4135"],"gpt_icon":0},{"id":"2608871324","title":"Replimune Reports Fiscal Third Quarter 2026 Financial Results and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2608871324","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608871324?lang=en_us&edition=fundamental","pubTime":"2026-02-03 21:00","pubTimestamp":1770123600,"startTime":"0","endTime":"0","summary":"April 10, 2026 Target Action Date for RP1 in Advanced MelanomaWOBURN, Mass., Feb.  03, 2026  (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/02/03/3230977/0/en/Replimune-Reports-Fiscal-Third-Quarter-2026-Financial-Results-and-Provides-Corporate-Update.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ORR"],"gpt_icon":0},{"id":"2607740100","title":"Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Provides a Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2607740100","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607740100?lang=en_us&edition=fundamental","pubTime":"2026-01-29 05:01","pubTimestamp":1769634060,"startTime":"0","endTime":"0","summary":"First patients dosed in DAYBreak registrational program for bexobrutideg in relapsed/refractory CLL Presented Phase 1 results at ASH 2025 that support bexobrutideg’s potential best-in-class profile in","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/01/28/3228040/0/en/Nurix-Therapeutics-Reports-Fourth-Quarter-and-Fiscal-Year-2025-Financial-Results-and-Provides-a-Corporate-Update.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2240825500.USD","LU0289739343.SGD","BK4585","LU1923621640.USD","BK4120","LU0511384066.AUD","LU2089284900.SGD","LU2362541513.USD","LU0289961442.SGD","LU1989772923.USD","WM","LU1585245621.USD","LU2362540622.SGD","LU0472753341.HKD","LU1712237335.SGD","BK4534","LU0124676726.USD","LU2023250504.SGD","LU2362541273.HKD","LU2041044095.USD","LU0158827948.USD","LU2028103732.USD","LU2089283258.USD","BK4533","LU2106854487.HKD","PFS","LU1917777945.USD","LU2092937221.SGD","LU0057025933.USD","LU2463526074.USD","BK4211","LU1430594728.SGD","LU0158827781.USD","LU1939255532.USD","LU1623119135.USD","LU2298064838.USD","ASH","LU2413666426.HKD","LU2023250843.SGD","BK4139","LU2229751404.USD","LU2308191902.HKD","ORR","BK4566","LU0069063385.USD","LU0689626769.HKD","LU1721428933.USD","NRIX","LU0347712357.USD","BK4195"],"gpt_icon":0},{"id":"2606919789","title":"Cardiff Oncology Announces Positive Update from its Randomized Phase 2 Trial of Onvansertib in First-line RAS-mutated mCRC","url":"https://stock-news.laohu8.com/highlight/detail?id=2606919789","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606919789?lang=en_us&edition=fundamental","pubTime":"2026-01-27 20:05","pubTimestamp":1769515500,"startTime":"0","endTime":"0","summary":"-Onvansertib added to FOLFIRI/bev first-line standard of care regimen showed dose-dependent improvement in overall response rates and durability trends as measured by progression-free survival in pati","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/01/27/3226345/0/en/Cardiff-Oncology-Announces-Positive-Update-from-its-Randomized-Phase-2-Trial-of-Onvansertib-in-First-line-RAS-mutated-mCRC.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0348723411.USD","BK4195","LU1548497426.USD","LU1861219969.SGD","ORR","BK4141","IE00BD6J9T35.USD","LU0053671581.USD","ON","BK4588","LU0054578231.USD","LU1861215975.USD","LU2357305700.SGD","LU1720051108.HKD","LU1861220033.SGD","LU1978683503.SGD","LU1854103824.USD","BK4512","BK4161","BK4585","BK4605","LU1861214812.USD","LU2360107325.USD","ITT","LU0124384867.USD","IE00BZ199S13.USD","LU2298322129.HKD","LU0724618433.USD","PFS","BK4211","IE00BFMHRM44.USD","LU1854104046.USD","LU1720051017.SGD"],"gpt_icon":0},{"id":"2604113780","title":"Cogent Biosciences to Initiate New Drug Application (NDA) Submission for Bezuclastinib Under Real-Time Oncology Review (RTOR)","url":"https://stock-news.laohu8.com/highlight/detail?id=2604113780","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2604113780?lang=en_us&edition=fundamental","pubTime":"2026-01-20 21:00","pubTimestamp":1768914000,"startTime":"0","endTime":"0","summary":"- PEAK trial first ever study to demonstrate statistical significance over an active comparator in GIST patients, with bezuclastinib plus sunitinib combination demonstrating mPFS of 16.5 months and OR","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/01/20/3221679/0/en/Cogent-Biosciences-to-Initiate-New-Drug-Application-NDA-Submission-for-Bezuclastinib-Under-Real-Time-Oncology-Review-RTOR.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4089","LU1670628061.USD","BK4195","CCOI","BK4532","ORR","PFS","LU1670627923.USD","BK4211"],"gpt_icon":0},{"id":"2603400937","title":"Antengene Presents at JPM: Strong Clinical Data Update and Strategic Focus on Next-Generation ADCs and TCEs","url":"https://stock-news.laohu8.com/highlight/detail?id=2603400937","media":"prnewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603400937?lang=en_us&edition=fundamental","pubTime":"2026-01-16 09:00","pubTimestamp":1768525200,"startTime":"0","endTime":"0","summary":"SHANGHAI and HONG KONG, Jan. 16, 2026 /PRNewswire/ -- Antengene Corporation Limited , a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines forautoimmune disease, solid tumors and hematological malignancies indications, announced that it recently presented at the 44th Annual J.P. Morgan Healthcare Conference held in San Francisco. At the conference, Antengene shared the latest data and clinical development plans for its core clinical asset, ATG-022 , as well as R&D progress on ATG-125 , its steric hindrance masking AnTenGager T cell engager  platform, and other key preclinical programs.Advancing clinical development across 1L to 3L gastric cancer: Antengene is currently conducting the Phase I/II CLINCH study and","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/antengene-presents-at-jpm-strong-clinical-data-update-and-strategic-focus-on-next-generation-adcs-and-tces-302662555.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE0034235188.USD","IE00B3S45H60.SGD","LU0211328371.USD","LU0345770993.USD","LU1670627923.USD","IE00BFXG1179.USD","LU1629891620.HKD","ORR.AU","IE0034235295.USD","LU1064131342.USD","LU2065731478.USD","LU1084165304.USD","IE00BHPRN162.USD","CRS.AU","BK4534","LU0943347566.SGD","ORR","LU0208291251.USD","IND","LU2756315664.SGD","LU0417517546.SGD","LU0006306889.USD","LU0106831901.USD","IE00BKVL7J92.USD","LU1974910355.USD","IE00BN8TJ469.HKD","IND.AU","LU0820562030.AUD","LU0345769631.USD","LU0345770308.USD","LU0170899867.USD","LU2746668461.USD","ACR.AU","LU2023250843.SGD","BK4581","LU0820561818.USD","LU2430703095.HKD","CRS","LU1244550494.USD","ACR","LU2264538146.SGD","CR","LU0868494617.USD","BK7508","LU0106261372.USD","LU0251132253.USD","LU2106854487.HKD","LU0683600562.USD","LU0787776722.HKD"],"gpt_icon":0},{"id":"2603613538","title":"C4 Therapeutics Outlines Strategic Milestones to Advance Cemsidomide as a Potential Best-in-Class IKZF1/3 Degrader and Discovery Strategy Focused on Novel Targets in Clinically Validated Pathways","url":"https://stock-news.laohu8.com/highlight/detail?id=2603613538","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603613538?lang=en_us&edition=fundamental","pubTime":"2026-01-14 20:00","pubTimestamp":1768392000,"startTime":"0","endTime":"0","summary":"Cemsidomide Phase 2 MOMENTUM Trial On Track to Initiate in Q1 2026; Recommended Phase 2 Dose is 100 g Cemsidomide Phase 1b Trial in Combination With Elranatamab On Track to Initiate in Q2 2026 Interna","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/01/14/3218491/0/en/C4-Therapeutics-Outlines-Strategic-Milestones-to-Advance-Cemsidomide-as-a-Potential-Best-in-Class-IKZF1-3-Degrader-and-Discovery-Strategy-Focused-on-Novel-Targets-in-Clinically-Val.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CCCC","BK4139","ORR"],"gpt_icon":0},{"id":"2602054358","title":"ACCENT DATA PRESENTED AT 2026 ASCO GASTROINTESTINAL CANCER SYMPOSIUM","url":"https://stock-news.laohu8.com/highlight/detail?id=2602054358","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602054358?lang=en_us&edition=fundamental","pubTime":"2026-01-12 21:45","pubTimestamp":1768225500,"startTime":"0","endTime":"0","summary":"HIGHLIGHTS Results from the Phase 2a ACCENT trial in pancreatic cancer have been presented at the specialist conference ASCO Gastrointestinal Cancer SymposiumUpdated data analysis continues to show th","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/01/12/3216936/0/en/ACCENT-DATA-PRESENTED-AT-2026-ASCO-GASTROINTESTINAL-CANCER-SYMPOSIUM.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PFS","BK4195","BK4139","BK4211","ORR","INNMF"],"gpt_icon":0},{"id":"2602851062","title":"Press Release: Rigel Provides Business Update and 2026 Outlook","url":"https://stock-news.laohu8.com/highlight/detail?id=2602851062","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602851062?lang=en_us&edition=fundamental","pubTime":"2026-01-12 21:05","pubTimestamp":1768223100,"startTime":"0","endTime":"0","summary":"-- Preliminary fourth quarter 2025 total revenue of approximately $69.8. million, including net product sales of $65.4 million and contract. RBC-TI was achieved by 33%  of evaluable transfusion dependent. $275 to $290 million, including net product sales of $255 to $265 million,\"2025 was an excellent year for Rigel, marked by strong commercial execution with record net product sales; significant financial progress, including continued profitability and generation of $77 million in cash; and meaningful clinical advancement of R289 in lower-risk MDS, where we shared encouraging Phase 1b data,\" said Raul Rodriguez, Rigel's president and CEO. \"In 2026, we plan to continue to execute across all areas of the business -- driving sustained commercial performance, supporting our expanding clinical programs with a solid financial foundation, delivering preliminary results from the dose expansion phase of our R289 study and continuing to explore opportunities to add new products to our portfolio.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","R","RIGL","OS","ORR","BK4232","ASH","BK4022","LU2463526074.USD","BK4211","BK4109","BK4097","HTB"],"gpt_icon":0},{"id":"2602515003","title":"Press Release: Exelixis Announces Preliminary Fiscal Year 2025 Financial Results, Provides 2026 Financial Guidance and Outlines Key Priorities and Milestones for 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2602515003","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602515003?lang=en_us&edition=fundamental","pubTime":"2026-01-12 18:37","pubTimestamp":1768214220,"startTime":"0","endTime":"0","summary":"-- Cabozantinib franchise achieves approximately $2.123 billion in preliminary U.S. net product revenues for fiscal year 2025 --. -- Fiscal year 2026 net product revenues guidance of $2.325 billion - $2.425 billion --. -- Presentation and webcast at J.P. Morgan 2026 Healthcare Conference tomorrow, Monday, January 12 at 5:15 p.m. PT / 8:15 p.m. ET --. Exelixis, Inc.  today announced its preliminary unaudited financial results for the fiscal year 2025, provided financial guidance for fiscal year 2026 and delivered an update on its business. Exelixis anticipates 2026 will be a significant year of clinical, regulatory and commercial progress as the company grows its current cabozantinib business, works toward building a potential second commercial franchise with zanzalintinib and moves its earlier stage pipeline forward. As outlined at its December 2025 R&D Day, the company seeks to leverage its diverse pipeline and key clinical collaborations to build next-generation oncology franchises t","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4213","OS","BK4607","BK4232","BK4548","BK4613","NET","R","BK4211","BK4532","LU2065169927.USD","BK4022","BK4116","BK4097","LU0456854461.SGD","BK4560","BK4588","EXEL","BK4195","LU2065171311.SGD","LU2286300806.USD","RCC","BK4554","BK4585","CRC","LU2065170008.USD","LU0266512127.USD","ORR","LU2065171402.SGD","PFS"],"gpt_icon":0},{"id":"2602139483","title":"Cellectis Announces 2026 Strategy and Catalysts","url":"https://stock-news.laohu8.com/highlight/detail?id=2602139483","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602139483?lang=en_us&edition=fundamental","pubTime":"2026-01-09 05:30","pubTimestamp":1767907800,"startTime":"0","endTime":"0","summary":"NEW YORK, Jan.  08, 2026  (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene editing platform to de","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/01/08/3215815/0/en/Cellectis-Announces-2026-Strategy-and-Catalysts.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TIL","ASH","OS","BK4505","BK4109","LU2463526074.USD","BK4139","CLLS","ORR","BK4097"],"gpt_icon":0},{"id":"2601236783","title":"ALX Oncology Advances Separate Clinical Trials Evaluating Investigational CD47-Inhibitor Evorpacept and Novel EGFR-Targeted Antibody-Drug Conjugate ALX2004","url":"https://stock-news.laohu8.com/highlight/detail?id=2601236783","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601236783?lang=en_us&edition=fundamental","pubTime":"2026-01-08 21:30","pubTimestamp":1767879000,"startTime":"0","endTime":"0","summary":"- First patient dosed in Phase 2 ASPEN-09-Breast trial evaluating evorpacept in combination with trastuzumab and physician’s choice of chemotherapy in HER2-positive metastatic breast cancer; interim a","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/01/08/3215379/0/en/ALX-Oncology-Advances-Separate-Clinical-Trials-Evaluating-Investigational-CD47-Inhibitor-Evorpacept-and-Novel-EGFR-Targeted-Antibody-Drug-Conjugate-ALX2004.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4080","LU0266512127.USD","BK4213","PFS","ORR","LU0456854461.SGD","BK4097","BK4211","BK4231","ALX","CRC","BK4195","ADC","OS"],"gpt_icon":0},{"id":"2601361831","title":"Acrivon Therapeutics Announces Positive ACR-368 Phase 2b Endometrial Cancer Clinical Data with EU Expansion to Accelerate Enrollment, Initial ACR-2316 Clinical Data, and ACR-6840, its Next AP3-Enabled Development Candidate, Targeting CDK11","url":"https://stock-news.laohu8.com/highlight/detail?id=2601361831","media":"GlobeNewswire","labels":["productRelease","dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601361831?lang=en_us&edition=fundamental","pubTime":"2026-01-08 20:30","pubTimestamp":1767875400,"startTime":"0","endTime":"0","summary":"Electronic data capture (EDC) extract from the ongoing ACR-368 registrational-intent Phase 2b monotherapy trial in OncoSignature-positive (BM+) subjects with endometrial cancer (EC) showed 39% overall","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/01/08/3215277/0/en/Acrivon-Therapeutics-Announces-Positive-ACR-368-Phase-2b-Endometrial-Cancer-Clinical-Data-with-EU-Expansion-to-Accelerate-Enrollment-Initial-ACR-2316-Clinical-Data-and-ACR-6840-its.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ACR","LENZ","BK4139","EC","EDC","BK4201","BK4539","MSS","AAQC","ORR","BK4007","BK4156","BK4110","BK4113"],"gpt_icon":0},{"id":"1191068681","title":"ORR Reaches 89.5%! Zhixiang Jintai's BCMA/CD3 Bispecific Antibody Submits for Market Approval","url":"https://stock-news.laohu8.com/highlight/detail?id=1191068681","media":"Deep News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1191068681?lang=en_us&edition=fundamental","pubTime":"2026-01-08 19:46","pubTimestamp":1767872818,"startTime":"0","endTime":"0","summary":"On January 8, Chongqing Genrix Biopharmaceutical Co.,Ltd. announced that the conditional new drug application for its bispecific antibody drug GR1803 (velinotamig) has been accepted by the National...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0239","ORR","688443"],"gpt_icon":0},{"id":"2601870204","title":"BBOT Announces New Clinical Data Advancing Its Portfolio of Three Innovative and Differentiated RAS and PI3Kα Pipeline Programs","url":"https://stock-news.laohu8.com/highlight/detail?id=2601870204","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601870204?lang=en_us&edition=fundamental","pubTime":"2026-01-07 20:00","pubTimestamp":1767787200,"startTime":"0","endTime":"0","summary":"BBO-8520 monotherapy in patients withKRASG12C non-small cell lung cancer (NSCLC) showed a 65% objective response rate (ORR) and a 66% 6-month progression-free survival (PFS), with 83% of patients elig","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/01/07/3214384/0/en/BBOT-Announces-New-Clinical-Data-Advancing-Its-Portfolio-of-Three-Innovative-and-Differentiated-RAS-and-PI3K%CE%B1-Pipeline-Programs.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0266512127.USD","BK4195","BK4211","ET","BK4161","BBOT","LU0456854461.SGD","BK4588","BK4139","BK4190","BK4581","BK4218","BK4213","BK4144","BK4590","PFS","BK4561","ORR","CRC","BC","PR","SOC","PK","BK4181","BK4585","CR"],"gpt_icon":0},{"id":"2601178208","title":"Ziihera® (zanidatamab-hrii) Combinations Achieve Unprecedented Results in First-Line HER2+ Locally Advanced or Metastatic GEA including more than Two Years Median Overall Survival Benefit","url":"https://stock-news.laohu8.com/highlight/detail?id=2601178208","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601178208?lang=en_us&edition=fundamental","pubTime":"2026-01-07 02:34","pubTimestamp":1767724440,"startTime":"0","endTime":"0","summary":"Positive results from Phase 3 HERIZON-GEA-01 results support Ziihera as the HER2-targeted agent-of-choice in HER2+ first-line metastatic GEA and Ziihera plus chemotherapy to replace trastuzumab as the","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/01/06/3214055/0/en/Ziihera-zanidatamab-hrii-Combinations-Achieve-Unprecedented-Results-in-First-Line-HER2-Locally-Advanced-or-Metastatic-GEA-including-more-than-Two-Years-Median-Overall-Survival-Bene.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B19Z4B17.USD","PFS","BK4195","IE00B7SZL793.SGD","IE0031619046.USD","BK4157","ORR","BK4225","OS","LU0757428866.USD","HR","IE00B66KJ199.SGD","BK4097","BK4211","BK4203","LU1815336091.USD","AEIS"],"gpt_icon":0},{"id":"2601981841","title":"Alpha Tau Reports New Positive Results in Two Upcoming Presentations at ASCO GI 2026 Symposium Showcasing Immune-Preservation and High Disease Control in Montreal Pancreatic Cancer Alpha DaRT® Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2601981841","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601981841?lang=en_us&edition=fundamental","pubTime":"2026-01-06 22:00","pubTimestamp":1767708000,"startTime":"0","endTime":"0","summary":"- Final results from first pancreatic cancer study in Montreal demonstrate 81% disease control rate, or 87% excluding the first two patients - - Immune markers demonstrate immune system preservation n","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/01/06/3213682/0/en/Alpha-Tau-Reports-New-Positive-Results-in-Two-Upcoming-Presentations-at-ASCO-GI-2026-Symposium-Showcasing-Immune-Preservation-and-High-Disease-Control-in-Montreal-Pancreatic-Cancer.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ORR"],"gpt_icon":0},{"id":"1155028709","title":"Junce Bio Focuses on \"Lymphodepletion-Free\" Breakthrough in Solid Tumors, GC101 Expected to Submit Marketing Application in 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=1155028709","media":"Deep News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1155028709?lang=en_us&edition=fundamental","pubTime":"2025-12-30 10:51","pubTimestamp":1767063074,"startTime":"0","endTime":"0","summary":"Shanghai Junce Biotechnology Co., Ltd. (\"Junce Bio\"), a company focused on developing innovative cell therapies and drugs for solid tumors, has officially submitted a listing application to the Hong...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4505","TIL","ORR"],"gpt_icon":0},{"id":"2595834477","title":"HUTCHMED Announces NDA Acceptance in China with Priority Review Status for Fanregratinib in Second-Line Intrahepatic Cholangiocarcinoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2595834477","media":"GlobeNewswire","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2595834477?lang=en_us&edition=fundamental","pubTime":"2025-12-29 16:35","pubTimestamp":1766997300,"startTime":"0","endTime":"0","summary":"— NDA supported by results from a Phase II registration trial in China — —Second most common form of liver cancer after hepatocellular carcinoma, with generally poorer long-term survival in comparison","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/29/3210799/0/en/HUTCHMED-Announces-NDA-Acceptance-in-China-with-Priority-Review-Status-for-Fanregratinib-in-Second-Line-Intrahepatic-Cholangiocarcinoma.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PFS","BK4195","BK1191","BK4211","BK1588","OS","00013","BK4097","ORR","BK1587"],"gpt_icon":0},{"id":"1141687432","title":"Lung Cancer Frontline! \"Furmonertinib\" New Indication Proposed for Breakthrough Therapy Designation","url":"https://stock-news.laohu8.com/highlight/detail?id=1141687432","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1141687432?lang=en_us&edition=fundamental","pubTime":"2025-12-26 20:21","pubTimestamp":1766751717,"startTime":"0","endTime":"0","summary":"On December 25th, the CDE (Center for Drug Evaluation) website indicated that a new indication for Allist Pharmaceuticals' Furmonertinib is proposed to be included in the Breakthrough Therapy...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4195","ORR","BK4211","PFS"],"gpt_icon":0}],"pageSize":20,"totalPage":7,"pageCount":1,"totalSize":137,"code":"91000000","status":"200"}]}}